scholarly journals MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods

2017 ◽  
Vol 1 (12) ◽  
pp. 728-732 ◽  
Author(s):  
Mikhail Roshal ◽  
Juan A. Flores-Montero ◽  
Qi Gao ◽  
Maesa Koeber ◽  
Jessica Wardrope ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Single Tube ◽  
Color Tube ◽  
Key Points

Key Points Methods that use an MSKCC single 10-color tube or EuroFlow two 8-color tubes provide similar sensitivity in the detection of MRD in multiple myeloma.

scholarly journals The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice

Blood ◽  
2016 ◽  
Vol 127 (13) ◽  
pp. 1676-1686 ◽  
Author(s):  
Zubin Zhang ◽  
Jiefei Tong ◽  
Xiaowen Tang ◽  
Jiaxiang Juan ◽  
Biyin Cao ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Cell Proliferation ◽  
Tumor Growth ◽  
Ubiquitin Ligase ◽  
Nude Mice ◽  
Key Points

Key Points HERC4 is the first identified ubiquitin ligase that mediates c-Maf ubiquitination and degradation. HERC4 suppresses MM cell proliferation and delays MM tumor growth.

scholarly journals Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma

Blood ◽  
2017 ◽  
Vol 129 (26) ◽  
pp. 3452-3464 ◽  
Author(s):  
Michelle M. McDonald ◽  
Michaela R. Reagan ◽  
Scott E. Youlten ◽  
Sindhu T. Mohanty ◽  
Anja Seckinger ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Zoledronic Acid ◽  
Bone Mass ◽  
Fracture Resistance ◽  
Specific Protein ◽  
Key Points

Key Points Anti-sclerostin treatment increases bone mass and fracture resistance in MM Anti-sclerostin in combination with zoledronic acid is superior to zoledronic acid alone in increasing fracture resistance.

scholarly journals Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease

Blood ◽  
2014 ◽  
Vol 123 (16) ◽  
pp. 2504-2512 ◽  
Author(s):  
Jeffrey R. Sawyer ◽  
Erming Tian ◽  
Christoph J. Heuck ◽  
Joshua Epstein ◽  
Donald J. Johann ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
High Risk ◽  
Copy Number ◽  
High Risk Disease ◽  
Key Points ◽  
Gains And Losses

Key Points Jumping translocations of 1q12 (JT1q12) provide a mechanism for the deletion of 17p in cytogenetically defined high-risk myeloma. Sequential JT1q12s introduce unexpected copy number gains and losses in receptor chromosomes during subclonal evolution.

scholarly journals Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors

Blood ◽  
2016 ◽  
Vol 127 (11) ◽  
pp. 1481-1492 ◽  
Author(s):  
Brian M. Dulmovits ◽  
Abena O. Appiah-Kubi ◽  
Julien Papoin ◽  
John Hale ◽  
Mingzhu He ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Mechanism Of Action ◽  
Hematopoietic Progenitors ◽  
Transcriptional Reprogramming ◽  
Key Points ◽  
Globin Synthesis

Key Points Pomalidomide selectively targets BCL11A and SOX6 to induce γ-globin synthesis. The mechanism of action of pomalidomide during erythropoiesis is independent of IKZF1 degradation, in contrast to multiple myeloma.

scholarly journals Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System

Blood ◽  
2015 ◽  
Vol 126 (17) ◽  
pp. 1996-2004 ◽  
Author(s):  
Rowan Kuiper ◽  
Mark van Duin ◽  
Martin H. van Vliet ◽  
Annemiek Broijl ◽  
Bronno van der Holt ◽  
...  
Keyword(s):  
Gene Expression ◽  
Multiple Myeloma ◽  
Prognostic Value ◽  
Staging System ◽  
Risk Classification ◽  
Low Risk ◽  
Key Points ◽  
International Staging System

Key Points Combination of ISS and the EMC92 gene classifier is a novel clinically applicable risk classification for survival in multiple myeloma. ISS has clear independent additive prognostic value in combination with GEP classifiers or FISH markers.

scholarly journals Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma

Blood ◽  
2018 ◽  
Vol 131 (19) ◽  
pp. 2138-2150 ◽  
Author(s):  
Yi Jin ◽  
Kenian Chen ◽  
Ayla De Paepe ◽  
Eva Hellqvist ◽  
Aleksandra D. Krstic ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Regulatory Network ◽  
Chromatin Accessibility ◽  
Epigenetic Changes ◽  
Active Enhancer ◽  
Key Points ◽  
Gene Regulatory

Key Points Gene regulatory features in MM patients reveal a key regulatory network and epigenetic changes that underpin the disease.

scholarly journals Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study

2017 ◽  
Vol 1 (24) ◽  
pp. 2186-2192 ◽  
Author(s):  
Marianna Thordardottir ◽  
Ebba K. Lindqvist ◽  
Sigrun H. Lund ◽  
Rene Costello ◽  
Debra Burton ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Multiple Myeloma ◽  
Body Mass ◽  
Monoclonal Gammopathy ◽  
High Body Mass Index ◽  
Population Based ◽  
Population Based Study ◽  
Increased Risk ◽  
Key Points ◽  
Undetermined Significance

Key PointsObesity is not associated with MGUS or LC-MGUS. High body mass index during midlife is associated with increased risk of progressing from MGUS and LC-MGUS to MM and other LP diseases.

scholarly journals Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Blood ◽  
2016 ◽  
Vol 128 (19) ◽  
pp. 2297-2306 ◽  
Author(s):  
Inger S. Nijhof ◽  
Laurens E. Franssen ◽  
Mark-David Levin ◽  
Gerard M. J. Bos ◽  
Annemiek Broijl ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Low Dose ◽  
Phase 1 ◽  
Refractory Multiple Myeloma ◽  
Key Points

Key Points REP is an active combination in MM patients refractory to lenalidomide. REP is an all-oral and generally well-tolerated regimen.

scholarly journals An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma

Blood ◽  
2018 ◽  
Vol 131 (7) ◽  
pp. 746-758 ◽  
Author(s):  
Lydia Lee ◽  
Benjamin Draper ◽  
Neil Chaplin ◽  
Brian Philip ◽  
Melody Chin ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Chimeric Antigen Receptor ◽  
Binding Sites ◽  
Antigen Receptor ◽  
High Affinity ◽  
Dual Targeting ◽  
Key Points

Key Points APRIL is a compact, self-protein that binds 2 MM antigens (BCMA and TACI) with high affinity; we present an APRIL-based CAR. Dual-antigen targeting increases the availability of tumor-binding sites and reduces the risk of antigen-negative disease escape.

scholarly journals Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1

Blood ◽  
2016 ◽  
Vol 128 (14) ◽  
pp. 1834-1844 ◽  
Author(s):  
Jia-Nan Gong ◽  
Tiffany Khong ◽  
David Segal ◽  
Yuan Yao ◽  
Chris D. Riffkin ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Cell Lines ◽  
Myeloma Cell ◽  
Pivotal Role ◽  
Bcl2 Family ◽  
Key Points ◽  
Low Passage ◽  
Bh3 Mimetic

Key Points Only a minority of myeloma cell lines are killed when the prosurvival BCL2 or BCLXL are selectively inhibited with BH3 mimetic compounds. In contrast, targeting MCL1 readily killed ∼70% of the myeloma cell lines tested, including both low-passage and well-established ones.

Sign in / Sign up

Export Citation Format

Share Document